ARTICLE | Product Development
COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
April 10, 2020 1:06 AM UTC
At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic included advancement of COVID-19 vaccine candidates from CanSino and Arcturus and a clinical trial of Fujifilm’s antiviral.
Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) and CalciMedica Inc. each gained FDA’s permission to conduct a Phase II trial addressing inflammation due to SARS-CoV-2 infection...